Hjem › Virusinfeksjoner › District of Columbia › Washington
Kliniske studier for Virusinfeksjoner i Washington, DC
12 studier for Virusinfeksjoner søker deltakere på steder i og rundt Washington (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
RekruttererFase 3
- Research Site, Washington D.C.
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
RekruttererObservasjonsstudie
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
RekruttererObservasjonsstudie
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
RekruttererFase 3
- Georgetown University Medical Center, Washington D.C.
- Jadestone Clinical Research, Silver Spring · 7 mi unna
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
RekruttererFase 3
- Georgetown University Medical Center, Washington D.C.
- Emerson Clinical Research Institute, Washington D.C.
- Jadestone Clinical Research, Silver Spring · 7 mi unna
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
- George Washington University, Washington D.C.
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Viral Infections in Healthy and Immunocompromised Hosts
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Genetic Studies of Chronic Active Epstein-Barr Disease
RekruttererObservasjonsstudie
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
RekruttererFase 1
- Children's National Hospital, Washington D.C.
- National Institutes of Health (NIH), Bethesda · 7 mi unna
Virusinfeksjoner-studier i andre byer
- Boston, MA6 studier
- Houston, TX6 studier
- Hialeah, FL5 studier
- Baltimore, MD5 studier
- Atlanta, GA4 studier
- Cincinnati, OH4 studier
- Dallas, TX4 studier
- Columbus, OH4 studier
- Los Angeles, CA3 studier
- Worcester, MA3 studier
- Miami, FL3 studier
- Tampa, FL3 studier
Andre studier i Washington
- Kreft (alle typer)58 studier
- Ikke-småcellet lungekreft55 studier
- Brystkreft46 studier
- Metastatisk kreft43 studier
- Lungekreft41 studier
- Prostatakreft38 studier
- Fedme33 studier
- Kolorektal kreft29 studier
- Kardiovaskulær sykdom28 studier
- Blærekreft26 studier
- Akut myelogen leukemi24 studier
- Eggstokkreft23 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.